Xbrane Biopharma is a Swedish developer of biosimilar products. The lead product is Xlucane, a Lucentis biosimilar partnered with STADA and produced using an efficient manufacturing system. A triptorelin generic, Spherotide, is being sold in Iran.
More Xbrane Biopharma content >Investment summary
Xbrane, a leading innovative biosimilar development company, is moving into mammalian cell culture with announced plans for Xdivane, a biosimilar of the immunoncology blockbuster Opdivo (nivolumab, BMS). The company plans to launch Xdivane from 2026. Xbrane has issued guidance that its share of revenues from Xlucane, partnered with STADA and due for launch by Q122, could reach €100m. The XPLORE Phase III trial has enrolled its first patient, with its primary endpoint due in mid-2020. Our valuation remains SEK581m pending further information on Xdivane.
Y/E Dec |
Revenue (SEKm) |
EBITDA (SEKm) |
PBT (SEKm) |
EPS (fd) (öre) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2017A | 20.8 | (40.9) | (44.2) | (814.0) | N/A | N/A |
| 2018A | 20.5 | (8.0) | (13.1) | (213.0) | N/A | 5.2 |
| 2019E | 20.0 | (140.5) | (146.9) | (1927.0) | N/A | N/A |
| 2020E | 20.0 | (234.0) | (240.4) | (2896.0) | N/A | N/A |
Industry outlook
Xlucane competitors include bioeq and Formycon with Phase III data and Samsung Bioepis with a Phase III reporting primary data soon. Roche has a bispecific antibody, faricimab, entering Phase III after a good Phase II performance with one injection every 16 weeks. It is also trialling new Lucentis delivery systems.
Last updated on 06/06/2019Content on Xbrane Biopharma
Sector |
|---|
|
Healthcare
Access more Healthcare content
|
Share price graph
Balance sheet |
|
|---|---|
| Forecast net debt (SEKm) | 38.9 |
| Forecast gearing ratio (%) | 158 |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Professor Saeid Esmaeilzadeh | Chairman |
| Martin Åmark | CEO |
| Dr Paolo Sarmientos | Head of Controlled Release Generics |
| Siavash Bashiri | COO and Head of Biosimilars |
You may also be interested in…
- 4SC
- Abliva
- Acacia Pharma
- Acarix
- ADL Bionatur Solutions
- Adocia
- Allarity Therapeutics
- AlzeCure Pharma
- Apontis Pharma
- ASIT biotech
- Basilea Pharmaceutica
- BerGenBio
- BioPorto Diagnostics
- Bonesupport
- Brighter
- Cantargia
- Carmat
- Celyad
- Deinove
- Formycon
- Herantis Pharma
- Hybrigenics
- Immunicum
- Immunovia
- IRLAB Therapeutics
- Kiadis Pharma
- Laboratorios Farmacéuticos ROVI
- MagForce
- Medigene
- MOLOGEN
- Nanobiotix
- Newron Pharmaceuticals
- Nicox
- Nuevolution
- Oasmia Pharmaceutical
- Onxeo
- Orexo
- Oryzon Genomics
- OSE Immunotherapeutics
- Paion
- Pharnext
- Photocure
- Pixium Vision
- Polyphor
- Probiodrug
- Quantum Genomics
- RhoVac
- Ryvu Therapeutics
- Sequana Medical
- Targovax
- Transgene
- TxCell
- Ultimovacs
- Xintela